With the disposal of UK-based Alliance Medical Group (AMG) and the pending exit of Life Molecular Imaging, Life Healthcare has decisively stepped away from its international expansion strategy and repositioned itself as a focused South African health-care operator.
The new direction is built on three priorities: operational excellence, network optimisation and margin growth. Central to this strategy is a renewed focus on the core acute hospital business, the acceleration of complementary services such as dialysis and diagnostics, and a concerted effort to extract more value from the group’s existing infrastructure.
That means improving occupancy, tightening cost control and ensuring every facility contributes meaningfully to the bottom line.
The acute hospital network — responsible for 86% of group revenue — has a clear focus on lifting underperforming facilities to sustainable occupancy levels. In 2023, nearly a fifth of hospital beds operated below 60% occupancy — a threshold considered financially unsustainable. By the end of 2024, that figure had improved to 64%, reflecting the group’s disciplined effort to convert idle capacity into margin-generating assets.
The hospital segment is growing selectively, with 219 new beds planned — 79 of which are set to come online in the next financial year. These expansions are targeted at areas with demonstrated demand and infrastructure shortfalls. A standout example is the 140-bed greenfield hospital under development in Paarl, Western Cape. The region is underresourced in private health care, is experiencing consistent population growth and has limited access to advanced cardiac services.
Life Healthcare is also actively pursuing brownfield expansions — upgrades and extensions to existing facilities that offer quicker returns and lower risk. These projects are strategically concentrated in regions with growing demand and infrastructure gaps, particularly along South Africa’s east coast, and in the North West and Free State. Brownfield investments are capital-efficient, averaging R2.5m-R3m per bed, and typically generate returns above 20%.
Though it currently makes up only 9% of group revenue, Life Healthcare’s complementary services segment is positioned as a key growth engine with a dual role. Not only does it expand the group’s reach into outpatient care, it also plays a strategic role in boosting utilisation across the hospital network by feeding patient volumes into acute facilities. Since 2021, the company has rapidly scaled this part of the business, adding imaging centres, dialysis stations and PET-CT capabilities. Revenue has more than doubled over the past three years, now surpassing R2bn.
Life Healthcare’s complementary services segment is positioned as a key growth engine with a dual role
The goal is to extend Life’s reach beyond traditional inpatient care — where patients are admitted for overnight or longer stays — by offering services that support continuous, co-ordinated treatment across the patient journey. At the centre of this effort is the recently acquired Fresenius Medical Care renal care operation, which adds nearly 300 treatment stations and a well-established patient base across multiple provinces. Once fully integrated, the expanded dialysis offering is expected to support both revenue and margin growth.
Underpinning all of this is a relentless focus on operational efficiency. Procurement, head office costs and internal systems are all under review. Notably, incentives for senior staff are explicitly tied to performance beyond baseline expectations — a model that, while adding pressure to margins during strong years, signals a culture shift towards accountability.
The AMG disposal has significantly reinforced Life Healthcare’s balance sheet, bringing net debt to earnings before interest, tax, depreciation and amortisation down to just 0.45 times. This sharp deleveraging has translated into substantial interest savings, giving a lift to the bottom line. More importantly, it puts the company in a position of strength — resilient to external shocks and well equipped to pursue strategic opportunities. While management hasn’t committed to a fixed dividend policy, it has signalled a flexible approach to distributing excess capital.
Challenges remain. The health-care services division — which makes up 8% of group revenue and includes Life Nkanyisa, a provider focused largely on patients under government-funded health care — was hit hard by the nonrenewal of several public sector contracts. While demand for these services persists, the business remains exposed to the budget constraints of provincial departments.
Adding further pressure is the stagnation of South Africa’s medical aid base, which limits growth in the private health-care market and intensifies competition for a finite pool of insured patients. At the same time, the sector faces a critical shortage of trained nurses — a structural issue that not only constrains capacity expansion but also adds complexity and cost to daily operations.
Life Healthcare’s strategy to sweat hospital assets while expanding high-margin, non-acute services puts it on a solid footing for sustained profit growth. Trading on a forward earnings multiple of just 12, it looks undervalued — especially for a business in a defensive sector with a solid balance sheet. For investors looking for stability with upside, this stock may be just what the doctor ordered.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.